Table 1.
Baseline demographics and characteristics
| Baseline parameter | All patients (n = 120) |
Prophylaxis: cohort A (n = 88) |
Treatment: cohort B (n = 7) |
Treatment: cohort C (n = 25) |
|---|---|---|---|---|
| Demographics | ||||
| Mean age (years) | 48 | 47 | 48 | 50 |
| Male [n (%)] | 72 (60) | 57 (65) | 2 (29) | 13 (52) |
| Female [n (%)] | 48 (40) | 31 (35) | 5 (71) | 12 (48) |
| Lymphoma type [n (%)] | ||||
| Diffuse large B cell lymphoma | 80 (67.0) | 62 (70.5) | 6 (85.7) | 12 (48.0) |
| Lymphoblastic lymphoma | 11 (9.0) | 10 (11.4) | 0 (0.0) | 1 (4.0) |
| Primary mediastinal B cell lymphoma | 8 (7.0) | 6 (6.8) | 1 (14.3) | 1 (4.0) |
| Primary CNS lymphoma | 8 (7.0) | 0 (0.0) | 0 (0.0) | 8 (32.0) |
| Peripheral T cell lymphoma | 5 (4.0) | 5 (5.7) | 0 (0.0) | 0 (0.0) |
| Burkitt’s lymphoma | 4 (3.0) | 3 (3.4) | 0 (0.0) | 1 (4.0) |
| Mantle cell lymphoma | 4 (3.0) | 2 (2.3) | 0 (0.0) | 2 (8.0) |
| Systemic + measurable CNS disease [n (%)] | 14 (11.7) | 0 (0.0) | 0 (0.0) | 14 (56.0) |
| Isolated measurable CNS disease, n (%) | 11 (9.2) | 0 (0.0) | 0 (0.0) | 11 (44.0) |
| High risk (2–3 risk factorsa) [n (%)] | 84 (70) | 68 (77.3) | 7 (100) | 9 (36) |
| Two risk factors | 57 (47.5) | 51 (58.0) | 2 (28.6) | 4 (16.0) |
| Three risk factors | 27 (22.5) | 17 (19.3) | 5 (71.4) | 5 (20.0) |
| High risk: Special extranodal localizationb | 30 (25.0) | 17 (19.3) | 2 (28.6) | 11 (44.0) |
| High risk: Diagnosis (lymphoblastic and Burkitt’s lymphoma) | 15 (13.0) | 13 (14.80) | 0 (0.0) | 2 (8.0) |
| Pleocytosis (lymphocytes > 15/μl) [n (%)] | 25 (20.8) | 0 (0.0) | 7 (100 %) | 21 (84 %) |
CSF cerebrospinal fluid, CNS central nervous system
aRisk factors defined as International Prognostic Index score 3ne-belevated lactate dehydrogenase, and ≥2 extranodal sites
bPatients with involvement at special sites, including infiltration of vertebral column, orbits, sinuses, or testes were also considered at high risk